### Guideline Page and Request

- **Internal request:**
  - Institutional review comment to consider the inclusion of rituximab and hyaluronidase human injection for subcutaneous use.

- **External request:**
  - Submission request from Genentech, Inc: For your updating purposes, please consider the following trials:
    - SABRINA: Efficacy and Safety in FL patients
    - MabEase: Efficacy, Safety, and Patient Preference in DLBCL patients
    - PrefMab: Patient Preference in FL and DLBCL patients

### Panel Discussion/References

Based on the FDA approval and discussion data from clinical trials (noted references below), the panel consensus was to include rituximab and hyaluronidase human injection for subcutaneous use as an option. The following footnote was added as appropriate, “Rituximab and hyaluronidase human injection for subcutaneous use may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion. This substitution cannot be made for rituximab used in combination with ibritumomab tiuxetan.”


<table>
<thead>
<tr>
<th>Institution Vote</th>
</tr>
</thead>
<tbody>
<tr>
<td>YES</td>
</tr>
<tr>
<td>22</td>
</tr>
</tbody>
</table>